Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)

This study has been completed.
Sponsor:
Information provided by:
Merck KGaA
ClinicalTrials.gov Identifier:
NCT00215644
First received: September 15, 2005
Last updated: February 17, 2014
Last verified: February 2014